x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012911
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asp910 of human TKS5 protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SH3PXD2A |
| UniProt No. | Q5TCZ1 |
| Gene ID | 9644 |
| Gene Description | TKS5 is a scaffold protein expressed on invadosomes of both normal and transformed cell lines. Research studies suggest that TKS5 is functionally required for both the formation and invasive behavior of invadosomes. TKS5 has an N-terminal PX domain that mediates invadosome initiation and localization of MMP-rich vesicles to the invadosome. TKS5 also has five SH3 domains, which recruit ADAM family proteinases to the invadosome to degrade extracellular matrix. These SH3 domains interact with adaptor proteins to facilitate F-actin polymerization during invadosome formation. Src tyrosine kinase has been shown to phosphorylate TKS5 at Tyr557 and Tyr619, which was shown to be necessary and sufficient for TKS5-mediated invadopia formation and invasion. Elevated TKS5 expression is positively associated with invasive behavior of cancer cells, suggesting TKS5 may have prognostic potential in cancer. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
